LOAMU
TVTX icon

Lombard Odier Asset Management (USA)’s Travere Therapeutics TVTX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-150,000
Closed -$3.06M – 300
2020
Q2 		$3.06M Hold
150,000
– – 0.21% 121
2020
Q1 		$2.19M Hold
150,000
– – 0.23% 115
2019
Q4 		$2.13M Sell
150,000
-25,000
-14% -$319K 0.19% 129
2019
Q3 		$2.03M Sell
175,000
-25,000
-13% -$413K 0.19% 125
2019
Q2 		$4.02M Buy
200,000
+63,235
+46% +$1.25M 0.32% 89
2019
Q1 		$3.1M Hold
136,765
– – 0.25% 90
2018
Q4 		$3.1M Sell
136,765
-49,719
-27% -$1.24M 0.24% 107
2018
Q3 		$5.36M Sell
186,484
-66,083
-26% -$1.89M 0.39% 85
2018
Q2 		$6.88M Sell
252,567
-71,100
-22% -$1.89M 0.45% 58
2018
Q1 		$7.24M Sell
323,667
-43,326
-12% -$1.03M 0.52% 53
2017
Q4 		$7.73M Sell
366,993
-13,176
-3% -$301K 0.59% 55
2017
Q3 		$9.46M Sell
380,169
-219,831
-37% -$4.84M 0.67% 45
2017
Q2 		$11.6M Buy
600,000
+8,859
+1% +$161K 0.92% 30
2017
Q1 		$10.9M Sell
591,141
-106,459
-15% -$2.08M 1.03% 24
2016
Q4 		$13.2M Sell
697,600
-146,874
-17% -$3M 1.68% 8
2016
Q3 		$18.9M Sell
844,474
-238,098
-22% -$4.53M 1.75% 4
2016
Q2 		$19.3M Sell
1,082,572
-197,151
-15% -$3.19M 2.34% 3
2016
Q1 		$17.5M Buy
1,279,723
+135,003
+12% +$2.05M 2.38% 3
2015
Q4 		$22.1M Sell
1,144,720
-91,985
-7% -$1.84M 2.14% 4
2015
Q3 		$25.1M Sell
1,236,705
-145,244
-11% -$4.3M 2.19% 4
2015
Q2 		$45.8M Sell
1,381,949
-620,984
-31% -$17M 3.26% 3
2015
Q1 		$48M Buy
2,002,933
+252,933
+14% +$3.86M 3.83% 2
2014
Q4 		$21.4M Buy
1,750,000
+850,000
+94% +$8.8M 1.47% 11
2014
Q3 		$8.12M Buy
900,000
+300,000
+50% +$3.53M 0.56% 57
2014
Q2 		$7.04M Buy
600,000
+150,000
+33% +$2.03M 0.37% 74
2014
Q1 		$9.54M Buy
+450,000
New +$6.92M 0.37% 79

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s TVTX Position: Q3 2020 in Review

Lombard Odier Asset Management (USA) sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 150,000 shares — an estimated $3.06M sold.

Lombard Odier Asset Management (USA) first reported a position in TVTX in Q1 2014 and held it in 26 quarters. The position peaked at $48M in Q1 2015. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Lombard Odier Asset Management (USA) reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 150,000 Travere Therapeutics shares in Q3 2020, an estimated $3.06M.
  • Lombard Odier Asset Management (USA) first reported a position in Travere Therapeutics in Q1 2014 and held it in 26 quarters.
  • Lombard Odier Asset Management (USA)'s Travere Therapeutics position peaked at $48M in Q1 2015.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2020, filed 16 Nov 2020.